Sexual bother in men with advanced prostate cancer undergoing androgen deprivation therapy

Catherine Benedict, Lara Traeger, Jason R. Dahn, Michael H Antoni, Eric S. Zhou, Natalie Bustillo, Frank J. Penedo

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Introduction: Men with advanced prostate cancer (APC) undergoing androgen deprivation therapy (ADT) often experience distressing sexual side effects. Sexual bother is an important component of adjustment. Factors associated with increased bother are not well understood. Aims: This study sought to describe sexual dysfunction and bother in APC patients undergoing ADT, identify socio-demographic and health/disease-related characteristics related to sexual bother, and evaluate associations between sexual bother and psychosocial well-being and quality of life (QOL). Methods: Baseline data of a larger psychosocial intervention study was used. Pearson's correlation and independent samples t-test tested bivariate relations. Multivariate regression analysis evaluated relations between sexual bother and psychosocial and QOL outcomes. Main Outcome Measures: The Expanded Prostate Cancer Index Composite sexual function and bother subscales, Center for Epidemiologic Studies Depression Scale, Functional Assessment of Cancer Therapy-General, and Dyadic Adjustment Scale were the main outcome measures. Results: Participants (N=80) were 70 years old (standard deviation [SD]=9.6) and reported 18.7 months (SD=17.3) of ADT. Sexual dysfunction (mean=10.1; SD=18.0) was highly prevalent. Greater sexual bother (lower scores) was related to younger age (β=0.25, P=0.03) and fewer months of ADT (β=0.22, P=0.05). Controlling for age, months of ADT, current and precancer sexual function, sexual bother correlated with more depressive symptoms (β=-0.24, P=0.06) and lower QOL (β=0.25, P=0.05). Contrary to hypotheses, greater sexual bother was related to greater dyadic satisfaction (β=-0.35, P=0.03) and cohesion (β=-0.42, P=0.01). Conclusions: The majority of APC patients undergoing ADT will experience sexual dysfunction, but there is variability in their degree of sexual bother. Psychosocial aspects of sexual functioning should be considered when evaluating men's adjustment to ADT effects. Assessment of sexual bother may help identify men at risk for more general distress and lowered QOL. Psychosocial interventions targeting sexual bother may complement medical treatments for sexual dysfunction and be clinically relevant, particularly for younger men and those first starting ADT.

Original languageEnglish
Pages (from-to)2571-2580
Number of pages10
JournalJournal of Sexual Medicine
Volume11
Issue number10
DOIs
StatePublished - Jan 1 2014

Fingerprint

Androgens
Prostatic Neoplasms
Social Adjustment
Quality of Life
Therapeutics
Outcome Assessment (Health Care)
Depression
Epidemiologic Studies
Multivariate Analysis
Regression Analysis
Demography
Health

Keywords

  • Androgen Ablation
  • Androgen Deprivation
  • Depressive Symptoms
  • Erectile Dysfunction
  • Hormone Therapy
  • Prostate Cancer
  • Quality of Life
  • Relationship Functioning
  • Sexual Bother
  • Sexual Dysfunction
  • Sexual Function

ASJC Scopus subject areas

  • Urology
  • Obstetrics and Gynecology
  • Reproductive Medicine

Cite this

Benedict, C., Traeger, L., Dahn, J. R., Antoni, M. H., Zhou, E. S., Bustillo, N., & Penedo, F. J. (2014). Sexual bother in men with advanced prostate cancer undergoing androgen deprivation therapy. Journal of Sexual Medicine, 11(10), 2571-2580. https://doi.org/10.1111/jsm.12645

Sexual bother in men with advanced prostate cancer undergoing androgen deprivation therapy. / Benedict, Catherine; Traeger, Lara; Dahn, Jason R.; Antoni, Michael H; Zhou, Eric S.; Bustillo, Natalie; Penedo, Frank J.

In: Journal of Sexual Medicine, Vol. 11, No. 10, 01.01.2014, p. 2571-2580.

Research output: Contribution to journalArticle

Benedict, C, Traeger, L, Dahn, JR, Antoni, MH, Zhou, ES, Bustillo, N & Penedo, FJ 2014, 'Sexual bother in men with advanced prostate cancer undergoing androgen deprivation therapy', Journal of Sexual Medicine, vol. 11, no. 10, pp. 2571-2580. https://doi.org/10.1111/jsm.12645
Benedict, Catherine ; Traeger, Lara ; Dahn, Jason R. ; Antoni, Michael H ; Zhou, Eric S. ; Bustillo, Natalie ; Penedo, Frank J. / Sexual bother in men with advanced prostate cancer undergoing androgen deprivation therapy. In: Journal of Sexual Medicine. 2014 ; Vol. 11, No. 10. pp. 2571-2580.
@article{7500d6e803c94ecba9e82f2b3b095632,
title = "Sexual bother in men with advanced prostate cancer undergoing androgen deprivation therapy",
abstract = "Introduction: Men with advanced prostate cancer (APC) undergoing androgen deprivation therapy (ADT) often experience distressing sexual side effects. Sexual bother is an important component of adjustment. Factors associated with increased bother are not well understood. Aims: This study sought to describe sexual dysfunction and bother in APC patients undergoing ADT, identify socio-demographic and health/disease-related characteristics related to sexual bother, and evaluate associations between sexual bother and psychosocial well-being and quality of life (QOL). Methods: Baseline data of a larger psychosocial intervention study was used. Pearson's correlation and independent samples t-test tested bivariate relations. Multivariate regression analysis evaluated relations between sexual bother and psychosocial and QOL outcomes. Main Outcome Measures: The Expanded Prostate Cancer Index Composite sexual function and bother subscales, Center for Epidemiologic Studies Depression Scale, Functional Assessment of Cancer Therapy-General, and Dyadic Adjustment Scale were the main outcome measures. Results: Participants (N=80) were 70 years old (standard deviation [SD]=9.6) and reported 18.7 months (SD=17.3) of ADT. Sexual dysfunction (mean=10.1; SD=18.0) was highly prevalent. Greater sexual bother (lower scores) was related to younger age (β=0.25, P=0.03) and fewer months of ADT (β=0.22, P=0.05). Controlling for age, months of ADT, current and precancer sexual function, sexual bother correlated with more depressive symptoms (β=-0.24, P=0.06) and lower QOL (β=0.25, P=0.05). Contrary to hypotheses, greater sexual bother was related to greater dyadic satisfaction (β=-0.35, P=0.03) and cohesion (β=-0.42, P=0.01). Conclusions: The majority of APC patients undergoing ADT will experience sexual dysfunction, but there is variability in their degree of sexual bother. Psychosocial aspects of sexual functioning should be considered when evaluating men's adjustment to ADT effects. Assessment of sexual bother may help identify men at risk for more general distress and lowered QOL. Psychosocial interventions targeting sexual bother may complement medical treatments for sexual dysfunction and be clinically relevant, particularly for younger men and those first starting ADT.",
keywords = "Androgen Ablation, Androgen Deprivation, Depressive Symptoms, Erectile Dysfunction, Hormone Therapy, Prostate Cancer, Quality of Life, Relationship Functioning, Sexual Bother, Sexual Dysfunction, Sexual Function",
author = "Catherine Benedict and Lara Traeger and Dahn, {Jason R.} and Antoni, {Michael H} and Zhou, {Eric S.} and Natalie Bustillo and Penedo, {Frank J.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/jsm.12645",
language = "English",
volume = "11",
pages = "2571--2580",
journal = "Journal of Sexual Medicine",
issn = "1743-6095",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Sexual bother in men with advanced prostate cancer undergoing androgen deprivation therapy

AU - Benedict, Catherine

AU - Traeger, Lara

AU - Dahn, Jason R.

AU - Antoni, Michael H

AU - Zhou, Eric S.

AU - Bustillo, Natalie

AU - Penedo, Frank J.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Introduction: Men with advanced prostate cancer (APC) undergoing androgen deprivation therapy (ADT) often experience distressing sexual side effects. Sexual bother is an important component of adjustment. Factors associated with increased bother are not well understood. Aims: This study sought to describe sexual dysfunction and bother in APC patients undergoing ADT, identify socio-demographic and health/disease-related characteristics related to sexual bother, and evaluate associations between sexual bother and psychosocial well-being and quality of life (QOL). Methods: Baseline data of a larger psychosocial intervention study was used. Pearson's correlation and independent samples t-test tested bivariate relations. Multivariate regression analysis evaluated relations between sexual bother and psychosocial and QOL outcomes. Main Outcome Measures: The Expanded Prostate Cancer Index Composite sexual function and bother subscales, Center for Epidemiologic Studies Depression Scale, Functional Assessment of Cancer Therapy-General, and Dyadic Adjustment Scale were the main outcome measures. Results: Participants (N=80) were 70 years old (standard deviation [SD]=9.6) and reported 18.7 months (SD=17.3) of ADT. Sexual dysfunction (mean=10.1; SD=18.0) was highly prevalent. Greater sexual bother (lower scores) was related to younger age (β=0.25, P=0.03) and fewer months of ADT (β=0.22, P=0.05). Controlling for age, months of ADT, current and precancer sexual function, sexual bother correlated with more depressive symptoms (β=-0.24, P=0.06) and lower QOL (β=0.25, P=0.05). Contrary to hypotheses, greater sexual bother was related to greater dyadic satisfaction (β=-0.35, P=0.03) and cohesion (β=-0.42, P=0.01). Conclusions: The majority of APC patients undergoing ADT will experience sexual dysfunction, but there is variability in their degree of sexual bother. Psychosocial aspects of sexual functioning should be considered when evaluating men's adjustment to ADT effects. Assessment of sexual bother may help identify men at risk for more general distress and lowered QOL. Psychosocial interventions targeting sexual bother may complement medical treatments for sexual dysfunction and be clinically relevant, particularly for younger men and those first starting ADT.

AB - Introduction: Men with advanced prostate cancer (APC) undergoing androgen deprivation therapy (ADT) often experience distressing sexual side effects. Sexual bother is an important component of adjustment. Factors associated with increased bother are not well understood. Aims: This study sought to describe sexual dysfunction and bother in APC patients undergoing ADT, identify socio-demographic and health/disease-related characteristics related to sexual bother, and evaluate associations between sexual bother and psychosocial well-being and quality of life (QOL). Methods: Baseline data of a larger psychosocial intervention study was used. Pearson's correlation and independent samples t-test tested bivariate relations. Multivariate regression analysis evaluated relations between sexual bother and psychosocial and QOL outcomes. Main Outcome Measures: The Expanded Prostate Cancer Index Composite sexual function and bother subscales, Center for Epidemiologic Studies Depression Scale, Functional Assessment of Cancer Therapy-General, and Dyadic Adjustment Scale were the main outcome measures. Results: Participants (N=80) were 70 years old (standard deviation [SD]=9.6) and reported 18.7 months (SD=17.3) of ADT. Sexual dysfunction (mean=10.1; SD=18.0) was highly prevalent. Greater sexual bother (lower scores) was related to younger age (β=0.25, P=0.03) and fewer months of ADT (β=0.22, P=0.05). Controlling for age, months of ADT, current and precancer sexual function, sexual bother correlated with more depressive symptoms (β=-0.24, P=0.06) and lower QOL (β=0.25, P=0.05). Contrary to hypotheses, greater sexual bother was related to greater dyadic satisfaction (β=-0.35, P=0.03) and cohesion (β=-0.42, P=0.01). Conclusions: The majority of APC patients undergoing ADT will experience sexual dysfunction, but there is variability in their degree of sexual bother. Psychosocial aspects of sexual functioning should be considered when evaluating men's adjustment to ADT effects. Assessment of sexual bother may help identify men at risk for more general distress and lowered QOL. Psychosocial interventions targeting sexual bother may complement medical treatments for sexual dysfunction and be clinically relevant, particularly for younger men and those first starting ADT.

KW - Androgen Ablation

KW - Androgen Deprivation

KW - Depressive Symptoms

KW - Erectile Dysfunction

KW - Hormone Therapy

KW - Prostate Cancer

KW - Quality of Life

KW - Relationship Functioning

KW - Sexual Bother

KW - Sexual Dysfunction

KW - Sexual Function

UR - http://www.scopus.com/inward/record.url?scp=84908505298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908505298&partnerID=8YFLogxK

U2 - 10.1111/jsm.12645

DO - 10.1111/jsm.12645

M3 - Article

C2 - 25059094

AN - SCOPUS:84908505298

VL - 11

SP - 2571

EP - 2580

JO - Journal of Sexual Medicine

JF - Journal of Sexual Medicine

SN - 1743-6095

IS - 10

ER -